Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-003: Zilovertamab vedotin plus R-GemOx vs R-GemOx in relapsed/refractory DLBCL
jRCT2011250068Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experienced an adverse event, Number of participants who discontinued study treatment due to an adverse event and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2011250068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250068.